Leading the Way
Sebela Pharmaceuticals Announces U.S. Launch of SUTAB® Tablets, An Alternative to Liquid Colonoscopy Preparation
Sebela Pharmaceuticals is uniquely positioned for significant growth organically and through acquisitions, in-licensing and partnerships. We offer market-leading treatments in gastroenterology, colorectal cancer prevention, dermatology and women’s health, including:
SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) Tablets, a sulfate-based tablet preparation for colonoscopy
See Full Prescribing Information and Medication Guide
SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution, the #1 prescribed branded bowel prep kit1
Click here for Full Prescribing Information and Medication Guide
NAFTIN® GEL 2% (Naftifine HCl), the #1 prescribed brand for interdigital tinea pedis1
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.
WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.
Please click here for full Prescribing Information about NAFTIN GEL 2%.
Sebela Pharmaceuticals provides resources to healthcare providers including product samples, patient savings cards and patient educational materials. To find a local Sebela Pharmaceuticals sales representative or to request support materials, please call the Sebela Pharmaceuticals Promotional Support line at 1-888-246-1207 or click below.
Sebela Pharmaceuticals’ Commitment
Sebela Pharmaceuticals is committed to improving patients’ lives by developing, marketing, and selling differentiated brands of prescription pharmaceuticals for patients whose needs are not adequately satisfied. Sebela Pharmaceuticals’ commercial activities are focused on niche therapeutic markets in the United States, including gastroenterology, colorectal cancer prevention, dermatology and women’s health.
REFERENCE: 1. IQVIA. National Prescription Audit Report. March 2021.